After Skin Cancer Treatment: Scar Management, Surveillance, and Prevention — A Living Review

The Follow-Up Phase Has Three Different Jobs

Treatment completion is a transition, not a discharge from clinical reasoning. The incision or reconstruction may be closed, but the scar is still remodeling. The treated cancer may be controlled, but recurrence risk is not identical across tumors. The carcinogenic field remains exposed to the same ultraviolet history, immune context, and inherited susceptibility that helped produce the first cancer.

The cleanest way to organize aftercare is to separate three questions:

1. How is the treated site healing and maturing? This includes scar symptoms, contour, function, and the possibility that an apparent scar change is not benign.
2. What cancer surveillance is needed? This includes local recurrence, regional or distant disease when relevant, and additional primary skin cancers.
3. What future risk can be reduced? This includes ultraviolet exposure, indoor tanning, medication or immune context, selected chemoprevention, and family risk communication.

Conflating these jobs creates predictable errors. A routine scar visit is not automatically an adequate total-body skin examination. A normal scar does not eliminate the risk of a new primary elsewhere. A sunscreen recommendation does not replace surveillance. A scan is not a better version of a skin examination when the disease and stage do not justify imaging.

Scar Maturation: A Moving Picture, Not a Snapshot

A fresh surgical scar is biologically active. Collagen is being deposited, degraded, and reorganized; vascularity and inflammation are changing; mechanical forces are acting across the wound; and contraction can alter nearby landmarks. Early redness, firmness, mild elevation, sensitivity, itch, numbness, or unevenness may improve without intervention. Conversely, progressive thickening, persistent symptoms, distortion, or growth beyond the original wound can reveal a pathologic trajectory.

The strongest Skin Trust reconstruction core finding for expectation-setting is prospective rather than cosmetic rhetoric: in a multicenter cohort of 990 patients undergoing facial Mohs surgery, patient-reported aesthetic satisfaction and quality-of-life outcomes continued to improve through one year.¹ This does not establish a universal maturity date. It establishes a better default conversation: the appearance at several weeks is not the appearance at several months, and the appearance at several months may not be the final result.

Normal evolution, hypertrophic scar, and keloid

A normally maturing scar generally becomes less vascular, less firm, and less conspicuous over time, although residual line, pigment change, contour difference, numbness, or textural mismatch may persist.

A hypertrophic scar is raised and often erythematous or symptomatic but remains within the boundaries of the original wound. A keloid extends beyond those boundaries and has a stronger tendency to persist or recur. The distinction matters because the natural history and treatment expectations differ, although clinical features can overlap or form a spectrum. Site, tension, skin type, personal or family keloid history, wound depth, inflammation, and prior treatment all modify risk.^2,9

The phenotype is more useful than the adjective “bad.” Clinicians should define the dominant problem:

The Safety Boundary: A Scar Does Not Get a Free Pass

Recurrence, a new adjacent primary tumor, inflammation, infection, suture reaction, neuroma, and ordinary remodeling can overlap clinically. A new or enlarging nodule, persistent ulceration, recurrent bleeding, nonhealing surface, progressive pain, numbness, fixation, or unexplained change within or beside a treatment site deserves examination.^11,14

That statement should not make every pink scar alarming. It should prevent the opposite mistake: assuming that every change at an operative site is “just scar tissue.” The appropriate next step is clinical assessment and, when indicated, dermoscopy, palpation, comparison with prior photographs, imaging, or tissue diagnosis. A photograph alone may be insufficient when depth, fixation, nerve symptoms, or regional nodes matter.

Scar Management: Match the Tool to the Phenotype

No intervention can promise an invisible scar. The clinical aim is narrower and more useful: reduce symptoms, improve color or contour, protect function, and make the scar less conspicuous without creating a worse tradeoff.

Observation and time

Observation is not therapeutic neglect when the trajectory is favorable. It avoids treating transient redness, firmness, or thickness that is already improving. It also allows the dominant problem to declare itself. The decision to wait should still be active: define what change is expected, when reassessment will occur, and what feature would trigger earlier review.

Silicone gel and silicone sheeting

Silicone has the most portable low-risk evidence among topical scar strategies. A 2020 meta-analysis included six randomized trials and 375 patients. Compared with placebo or no treatment, topical silicone gel improved Vancouver Scar Scale pigmentation, height, and pliability scores; gel and sheets appeared comparably effective.³

The evidence supports a modest option, not a guarantee. Trials were small and heterogeneous, and scar type, location, timing, adherence, and outcome measurement varied. Formulation can therefore be selected according to anatomy, irritation, visibility, and the patient's ability to use it consistently. The treating clinician should confirm that the surface is sufficiently healed for the proposed product; a general review should not convert silicone evidence into a universal postoperative start date.

Massage

Massage is commonly recommended, but the evidence base is frequently overstated. A systematic review and meta-analysis found improvements in several outcomes among burn-scar populations, yet protocols varied and the evidence remained inconsistent.⁸ Those data do not establish one technique, pressure, frequency, or start time after Mohs surgery or excision.

Massage may be reasonable for a selected closed scar when mobility, tightness, or symptoms are relevant, but it must be reconciled with the actual repair. A graft, flap, free margin, irradiated field, second-intention wound, or incompletely healed surface may require a different plan. This article intentionally does not prescribe that plan.

Topical vitamin E and the “natural” product problem

Topical vitamin E is memorable, inexpensive, and poorly supported. In a small double-blind split-scar trial of 15 patients after skin-cancer surgery, it did not improve cosmetic appearance; 33% of participants developed contact dermatitis.⁴ The sample was small, but the study undermines routine recommendation: there was no demonstrated benefit and a meaningful irritation signal.

The broader lesson is that a product's familiarity does not establish scar benefit. Fragrance, botanicals, adhesives, and multiple layered products can create dermatitis that makes a scar redder and more symptomatic. Add one evidence-based intervention for a defined purpose, then judge the trajectory.

Intralesional treatment for raised scars

Intralesional corticosteroids can reduce height, firmness, itch, and pain in hypertrophic scars and keloids. Combinations with agents such as 5-fluorouracil are used for selected lesions. The literature supports activity but not a universally curative regimen; studies are small, outcome definitions vary, and long-term recurrence is incompletely measured.⁹

Treatment must balance benefit against atrophy, telangiectasia, pigment change, ulceration, injection pain, and recurrence. The keloid tendency is not removed merely because a lesion flattens. Serial photographs and consistent measurement are more informative than an undocumented impression that the scar “looks better.”

Vascular and fractional lasers

Laser treatment should be organized by target. Pulsed-dye laser primarily addresses vascular redness. Fractional nonablative or ablative devices target remodeling and texture at different depths. Skin type, pigmentary risk, scar maturity, anatomy, device settings, operator expertise, and tolerance all matter.

In a randomized trial of 76 adults after skin surgery, 52 completed 36-week follow-up. Three sessions of combined pulsed-dye and nonablative fractional laser produced greater patient- and observer-rated improvement than no laser treatment, including improvement in thickness, stiffness, vascularity, and erythema.⁵ By contrast, a small trial found no benefit from one pulsed-dye treatment at suture removal.⁶ A meta-analysis of seven randomized trials supports pulsed-dye laser for selected surgical-scar features while also showing how heterogeneous the protocols remain.⁷

Together, these data support a planned, phenotype-directed course rather than the claim that “early laser” or one device is universally best. Treat redness as redness, texture as texture, and pigment with particular respect for skin type.

Resurfacing, dermabrasion, camouflage, and revision

Resurfacing and dermabrasion may soften a step-off or textural mismatch when the scar and surrounding skin can tolerate controlled injury. Camouflage, tint, hairstyle, and optical strategies are legitimate quality-of-life tools rather than admissions of therapeutic failure.

Surgical revision may narrow, redirect, release, or recontour a mature scar. It trades one scar for a better-planned scar; it does not erase scar biology. Timing depends on trajectory, symptoms, functional distortion, cancer status, and whether a less invasive option can address the dominant problem. Earlier intervention can be justified when function is threatened. Purely cosmetic revision is usually easier to judge after the scar has declared itself.

Surveillance After Skin Cancer: Define the Event

“Follow-up” is not one intervention. The visit must be designed around the event most worth detecting.

Local, regional, and distant recurrence

The surveillance architecture depends on the cancer. A low-risk keratinocyte carcinoma treated with complete margin control presents a different recurrence problem from a deeply invasive cSCC with perineural involvement or a stage III melanoma. Examination of the scar may be enough for one patient; another may also need regional-node assessment, symptom review, imaging, oncology coordination, or treatment-toxicity monitoring.

For cSCC, current guidance is most intensive during the first two years and then spaces visits according to tumor risk and immune status.^14,15 “Every three months forever” is not a universal rule. High-risk pathology, recurrence, immune suppression, nodal disease, symptoms, and treatment can justify a closer pathway.

For melanoma, stage drives intensity. Current NCCN guidance does not recommend routine imaging for asymptomatic stage IA through IIA disease. Selected patients with stage IIB through IV disease and no evidence of disease may receive time-limited imaging as part of a coordinated plan (NCCN category 2B).¹² A scan is useful when the pretest risk and possible action justify it. It is not a generic reassurance test.

New primary skin cancers

For many survivors, the most likely future skin-cancer event is not recurrence at the original scar. It is another primary tumor elsewhere.

In a prospective cohort of 1,284 immunocompetent patients with keratinocyte carcinoma, the five-year risk of another keratinocyte carcinoma was 40.7% after a first lifetime tumor and 82.0% after a nonfirst tumor.¹⁶ These are cohort estimates, not individual forecasts, but the gradient is clinically useful: repeated tumors identify a substantially higher-burden group.

Melanoma survivors also retain a lifelong second-primary risk. A SEER cohort reported cumulative second-primary melanoma incidence of 3.9% at five years and 6.7% at ten years.¹³ This is why skin surveillance continues even after the stage-specific recurrence-imaging window ends.

BCC adds a different lesson: slow tumors can recur late. In randomized long-term follow-up of facial BCC, more than half of the recurrences after treatment of primary tumors appeared beyond five years.¹⁷ A short clean interval is reassuring; it should not be mistaken for a permanent exemption from skin surveillance.

Treatment effects and function

Follow-up should also assess what treatment changed: eyelid closure, nostril position, lip mobility, sensation, range of motion, graft or flap contour, radiation change, lymphatic symptoms, or systemic-therapy toxicity. These findings may belong to the treating surgeon, dermatologist, oncologist, radiation oncologist, or another specialist. The patient's calendar should make ownership explicit.

What Should Happen Between Visits?

Self- and partner awareness provide longitudinal information that a periodic office examination cannot. Patients can notice evolution, a new lesion, recurrent bleeding, or a symptom that emerged after the last visit. They can use mirrors or photographs to reach difficult areas and ask a partner to inspect the scalp or back.

The safety claim must remain precise: self-examination can prompt evaluation, but it cannot prove that a lesion is harmless or replace risk-appropriate professional surveillance.^10,11,23 A rigid checklist can create false reassurance when a lesion is small, pale, rapidly growing, tender, ulcerated, or simply unlike the patient's other spots.

A practical between-visit escalation rule is broader than ABCDE: report a new, changing, bleeding, nonhealing, painful, numb, or distinctly different lesion, including a change in or near a treatment scar. New persistent node enlargement, unexplained systemic symptoms, or treatment-related concerns should be routed according to the original cancer and care team.

Prevention: Reduce Future Risk Without Promising Zero

Prevention after skin cancer is risk reduction, not immunity. It should be cumulative, realistic, and attached to the patient's pattern of exposure.

Layered ultraviolet protection

The Nambour randomized trial provides unusually direct prevention evidence. Over 4.5 years, daily SPF 15-plus sunscreen (labeled SPF 15+/16) did not significantly reduce BCC incidence but reduced the number of cSCC tumors, with a tumor-count rate ratio of 0.61 rather than a person-level risk ratio.¹⁸ Extended follow-up found 11 melanomas in the daily-sunscreen group and 22 in the discretionary-use group; the overall melanoma hazard ratio narrowly missed conventional statistical significance, while invasive melanoma was significantly lower.¹⁹ Small melanoma counts and an Australian setting limit precision, but the trial supports regular use rather than sunscreen nihilism.

Sunscreen is only one layer. Professional guidance recommends shade, protective clothing, a broad-brimmed hat, sunglasses, broad-spectrum water-resistant SPF 30 or higher on uncovered skin, and avoidance of indoor tanning.²⁵ Clothing often provides more reliable coverage than a thin or forgotten sunscreen layer. Sunscreen should not be used to extend exposure.

Behavioral plans work better when they fit the patient's life: outdoor occupation, sports, driving, gardening, medication photosensitivity, scalp exposure, skin tone, product tolerance, and prior cancer sites. The best plan is not the longest list; it is the set of protections the patient will actually repeat.

Nicotinamide: a bounded option

Nicotinamide is not a universal post-cancer vitamin. In the ONTRAC phase III trial, 386 immunocompetent adults with at least two keratinocyte cancers in the prior five years received nicotinamide 500 mg twice daily or placebo for 12 months. New keratinocyte cancers were 23% lower during treatment, but there was no evidence of benefit after discontinuation.²⁰

The population and clock belong in every retelling. The result does not establish benefit after one low-risk tumor, lifelong benefit, benefit after stopping, or replacement of surveillance and photoprotection. A 2023 phase III transplant-recipient trial did not show the same chemopreventive benefit.²¹ Patients should discuss contraindications, kidney or liver context, medication interactions, pregnancy, pill burden, and whether their tumor burden resembles the studied population with a clinician.

Transplant and other immunosuppressed populations

Repeated cSCC in a transplant recipient is a multidisciplinary problem. Systemic retinoids can reduce tumor burden in selected high-risk kidney recipients, and modification of immunosuppression may be considered in carefully selected cases. Toxicity, graft function, organ type, rejection risk, mortality signals, and competing medical priorities limit generalization.²²

No patient should stop or modify antirejection or immune-modifying treatment independently. Prevention decisions belong to dermatology and the transplant or prescribing team together.

Family Screening and Hereditary Risk

Family communication should be proportionate. Most skin cancers do not imply a high-penetrance inherited syndrome, yet family history can change risk assessment, especially for melanoma.

Melanoma guidelines advise patients that relatives have increased melanoma risk.²³ The useful message is not “everyone needs my schedule.” It is: tell close relatives the diagnosis, encourage them to learn their own skin, avoid indoor tanning and sunburn, and ask a clinician to assess their personal risk. Their phenotype, number and type of nevi, ultraviolet history, age, prior lesions, immune status, and the number and pattern of cancers in the family determine whether professional surveillance is warranted and how often.

Genetic counseling is different from routine family awareness. NCCN v2.2026 and NCI guidance support considering counseling and CDKN2A testing when there are more than two (equivalent to three or more) invasive cutaneous melanomas or a combination of invasive melanoma, pancreatic cancer, and/or astrocytoma in the personal or family history.^12,24 Multiple primary melanomas, young onset, or other syndrome-associated tumors can further strengthen the case for a genetics review.

Counseling should precede casual panel testing. A positive result may change surveillance for the patient and relatives; a negative result does not erase familial or phenotypic risk. The goal is an interpretable family plan, not a decontextualized laboratory result.

A Practical Clinician Framework

At the end of treatment, document a compact plan that answers six questions:

1. Cancer control: What was treated, how were margins or response assessed, and what features determine recurrence risk?
2. Scar trajectory: What changes are expected over the next several months, and which functional or symptomatic changes should trigger earlier review?
3. Surveillance owner: Which clinician examines the treated site, regional nodes when relevant, and the rest of the skin?
4. Schedule logic: Why is the next visit at this interval, and what would shorten or lengthen it?
5. Between-visit action: Which changes should the patient report rather than waiting for the next appointment?
6. Prevention and family: Which ultraviolet protections are realistic, does the patient meet a chemoprevention discussion threshold, and what should relatives know?

This framework is deliberately diagnosis-agnostic at the top level and diagnosis-specific underneath. It gives every survivor the same questions without giving every survivor the same answers.